A nuchal translucency scan, commonly called an NT scan, is a first-trimester ultrasound that measures the small pocket of fluid at the back of a developing baby’s neck. That measurement, typically taken between 11 and 13 weeks of pregnancy, serves as one of the earliest indicators of chromosomal conditions like Down syndrome and certain structural problems, particularly heart defects. The scan itself is brief, painless, and noninvasive, but the number it produces carries outsized importance in prenatal care because it shapes decisions about further testing for the remainder of the pregnancy.
What Happens During the Scan
The ultrasound is performed transabdominally, with the sonographer positioning the probe to get a side-on (sagittal) view of the baby. The fetus needs to fill roughly three-quarters of the screen, and the measurement is taken at the widest point of the translucent space between the skin and the soft tissue at the back of the neck.1Fertility, Gynecology and Andrology. Are Fetal Nuchal Translucency Thickness and Crown-rump Length Associated with Maternal Hematological and Biochemical Profile? Getting that image correctly is trickier than it sounds. The baby’s position matters enormously: if the fetus is curled up or facing the wrong way, distinguishing the skin from the surrounding amniotic membrane can be difficult, which is one reason why measurement quality varies between practitioners.2PubMed. Comparison between two- and three-dimensional ultrasound measurements of nuchal translucency
The timing window is narrow for a reason. Before about 11 weeks, the baby is too small to measure reliably. After roughly 13 weeks and 6 days, the fluid space tends to drain naturally through the developing lymphatic system regardless of whether anything is wrong. That leaves a window of roughly three weeks in which the measurement is clinically useful.
Why the Fluid Collects
All babies have some fluid at the back of the neck in early pregnancy. When that space is thicker than expected, several things could be going on. Research has identified three main pathways. First, the heart may not be pumping efficiently, causing fluid to back up. Second, the composition of the connective tissue in the neck skin may be altered, making it hold more fluid. Third, the lymphatic system that normally drains fluid from tissues may not have developed properly yet.3Human Reproduction Update. Pathophysiology of increased nuchal translucency: a review of the literature These mechanisms can overlap, and different underlying conditions tend to trigger different ones. A chromosomal abnormality might affect all three. A heart defect might primarily cause the first. A genetic syndrome might primarily affect the third.
Screening for Down Syndrome and Other Chromosomal Conditions
The NT measurement was first proposed as a screening tool for Down syndrome in the early 1990s, when researchers showed that combining it with maternal age could predict the risk of trisomy with a sensitivity of about 85% at a 5% false-positive rate.4PubMed. Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancy That was a significant leap from screening by maternal age alone, which caught only about 20 to 30% of cases.
Used on its own, NT is a moderate screening tool. A large meta-analysis pooling data from over 225,000 low-risk pregnancies found that NT alone picks up roughly 68% of Down syndrome cases, with about a 4% false-positive rate.5PubMed Central. The Diagnostic Performance of Nuchal Translucency Alone as a Screening Test for Down Syndrome: A Systematic Review and Meta-analysis That means about a third of affected pregnancies would be missed if NT were the only tool used, which is why it is almost never used in isolation today.
The scan also flags risk for other trisomies, including trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome), which are associated with thicker nuchal measurements and abnormal blood flow patterns through a small vessel called the ductus venosus.6PubMed. Early diagnosis of trisomy 21, trisomy 18 and trisomy 13 using nuchal translucency thickness and ductus venosus blood flow waveform in West China
Combined First-Trimester Screening
In standard practice, NT is one part of a three-pronged first-trimester screen. The other two components are blood markers drawn from the mother: PAPP-A and free beta-hCG.7PubMed Central. First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free β-hCG for Down Syndrome, Patau Syndrome and Edward Syndrome These markers tend to show characteristic patterns in affected pregnancies: PAPP-A is often lower than average and free beta-hCG is often higher. By feeding all three results into a risk calculation along with maternal age, the combined screen performs substantially better than any single component.
How much better depends partly on timing. When the blood draw and the ultrasound both happen at 11 weeks, the combined screen can detect about 92% of Down syndrome cases at a 3% false-positive rate. At 12 weeks, detection drops to about 85% for the same false-positive rate, and at 13 weeks it falls further to about 79%.8PubMed. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A The reason is that the blood markers are most discriminating earlier in the window. If your provider schedules the combined screen, getting it done closer to 11 or 12 weeks rather than waiting until 13 gives the test its best shot at accuracy.
Adding additional ultrasound markers during the same visit pushes detection even higher. When the sonographer also checks for a visible nasal bone, tricuspid valve flow, and ductus venosus flow, detection rates can reach roughly 94% at a 3% false-positive rate.9PubMed. First trimester ultrasound screening for Down syndrome based on maternal age, fetal nuchal translucency and different combinations of the additional markers nasal bone, tricuspid and ductus venosus flow Not every clinic routinely performs all of these additional checks, so the experience can vary depending on where you are seen.
NT and Heart Defects
Even when chromosomes are completely normal, an elevated NT measurement raises the odds of a congenital heart defect. The relationship is well established and roughly dose-dependent: the thicker the measurement, the higher the risk. Fetuses with an NT above 3 mm have about a 6% chance of a heart defect, and that rate climbs to about 20% when the measurement exceeds 5.5 mm.10PubMed Central. Nuchal Translucency and Congenital Heart Defects A study following nearly 700 fetuses with normal chromosomes but elevated NT found that the rate of major heart defects ranged from about 2% in the mildly elevated group (NT between 2.5 and 3.5 mm) to nearly 28% when NT was 6.5 mm or above.11PubMed. Structural heart defects associated with an increased nuchal translucency: 9 years experience in a referral centre
This is one of the strongest arguments for continuing to perform NT scans even in an era of advanced blood-based genetic testing. A blood test can tell you about chromosomes, but it cannot see a malformed heart valve. Fetal echocardiography, the specialized ultrasound used to examine the baby’s heart in detail, is typically recommended when the NT is significantly elevated, even if all genetic results come back normal.
Genetic Syndromes Beyond Chromosomal Abnormalities
An elevated NT in a fetus with a normal set of chromosomes can also point to single-gene disorders. Noonan syndrome is the most commonly identified, appearing in roughly 10% of euploid fetuses with increased NT.12PubMed. Testing for Noonan syndrome after increased nuchal translucency This condition affects heart development, growth, and facial features, and standard chromosome testing (karyotyping) does not detect it because the chromosomes themselves look normal.
Broader genetic sequencing can catch some of these cases. A systematic review found that when more advanced sequencing was performed on fetuses with elevated NT but normal chromosomes, about 4% had a disease-causing genetic variant that would otherwise have been missed. Noonan syndrome accounted for a notable share, and the likelihood of finding something increased when the NT was 5 mm or above.13PubMed. Diagnostic yield of next-generation sequencing in fetuses with isolated increased nuchal translucency: systematic review and meta-analysis This kind of testing is not routine for everyone with an elevated NT, but it may be offered when the measurement is very high and other explanations have been ruled out.
How NT Relates to Cell-Free DNA Screening
Cell-free DNA screening, often called NIPT, analyzes fragments of fetal DNA circulating in the mother’s blood. For the common trisomies it targets (21, 18, and 13), NIPT is more accurate than combined first-trimester screening. This has raised a recurring question in prenatal care: if NIPT is better at catching Down syndrome, do we still need the NT scan?
The answer, for now, is that NT catches things NIPT cannot. NIPT is designed to look at specific chromosomes and does not detect structural problems like heart defects, rarer chromosomal rearrangements, or single-gene syndromes. In a large study of over 450,000 pregnancies, there were 649 rare chromosomal abnormalities that NIPT would not have flagged. Of those, about 17% had an NT of 3.0 mm or above, meaning the ultrasound would have raised a flag that the blood test missed.14PubMed Central. The utility of nuchal translucency ultrasound in identifying rare chromosomal abnormalities not detectable by cell-free DNA screening That 17% catch rate is far from perfect, but it represents conditions that would otherwise go entirely undetected until later in pregnancy or after birth.
That said, the NT measurement’s ability to detect the chromosomal abnormalities that NIPT misses is limited. A recent study found that for anomalies not picked up by genome-wide NIPT, more than 90% of affected cases had an NT measurement below any commonly proposed threshold.15PubMed Central. How Useful is Nuchal Translucency in Detecting Chromosomal Abnormalities Missed by Genome-Wide NIPT and What Measurement Threshold Should Be Used? So NT is not a reliable safety net for the specific conditions NIPT was built to find but happened to miss. Its value alongside NIPT is primarily for structural anomalies and genetic syndromes rather than as a backup chromosomal screen.
Some screening models use NT as a first-line filter, sending only intermediate-risk patients for NIPT rather than offering the more expensive blood test to everyone. One analysis of this approach estimated it could achieve a 98% detection rate for Down syndrome, though the cost per detected case was substantially higher than traditional combined screening alone.16PubMed. First trimester contingent testing with either nuchal translucency or cell-free DNA. Cost efficiency and the role of ultrasound dating
What Happens After an Elevated NT
An elevated NT is not a diagnosis. It is a flag that prompts further investigation. The follow-up path depends on how high the measurement is and what the combined screening risk calculation suggests.
For many patients, the next step is either NIPT or an invasive diagnostic test such as chorionic villus sampling (CVS) or amniocentesis. These tests can confirm or rule out chromosomal abnormalities with near-complete accuracy. In one center’s experience, increased NT was one of the two most common reasons for performing CVS, and trisomy 21 was found in about 13% of cases where the indication was elevated NT specifically.17Turkish Journal of Women’s Health and Neonatology. Indications and results of prenatal invasive diagnosis (amniocentesis, chorionic villus sampling, cordocentesis): A tertiary center experience That means the remaining 87% of those cases came back with normal chromosomes, which underscores that most elevated NT results do not lead to a diagnosis of a chromosomal condition.
When chromosomes are normal, a detailed anatomy scan (usually around 20 weeks) and fetal echocardiography are typically recommended to look for structural problems. If those also come back clean, the outlook is very reassuring.
Outcomes When NT Is Elevated but Everything Else Looks Normal
This is often the scenario that causes the most anxiety: the NT is above the usual cutoff, but genetic testing and follow-up ultrasounds all look fine. Research on this group is broadly reassuring. In a follow-up study of 119 fetuses with increased NT but normal chromosomes, about 90% were structurally normal. Among the roughly 13% that did have structural anomalies detected on second-trimester ultrasound, heart defects were the most common, accounting for nearly half.18IIUM Medical Journal Malaysia. Outcome of Pregnancy in Chromosomally Normal Foetus with Increased Nuchal Translucency
The degree of elevation matters. About 97% of fetuses with NT at or above the 95th percentile (around 3.4 mm) but below the 99th percentile had a normal outcome. That rate dropped to about 80% when NT was at or above the 99th percentile (around 5.5 mm). Even at the higher end, most babies did fine, but the gap between 97% and 80% is meaningful enough that closer monitoring is warranted for very high measurements.
When the karyotype is normal and detailed second-trimester imaging reveals no structural problems, the rate of postnatal developmental delay and adverse outcomes does not appear to be significantly increased compared to the general population.19PubMed Central. Increased nuchal traslucency in normal karyotype fetuses That finding is one of the most important things for worried parents to hear: once the major problems have been ruled out by further testing, an elevated NT alone does not predict poor outcomes.
NT Screening in Twin Pregnancies
The scan works differently in twins, and the interpretation is more complex. In twin pregnancies, whether the babies share a placenta (monochorionic) or have separate placentas (dichorionic) matters far more than it does for singletons, because monochorionic twins face unique complications like twin-to-twin transfusion syndrome.
When one or both monochorionic twins have an elevated NT, the rate of structural anomalies is substantially higher than in dichorionic twins: about 15% versus 3% in one study. Twin-specific complications were also more common, occurring in roughly 30% of monochorionic pregnancies with elevated NT compared to about 9% of dichorionic ones.20PubMed Central. Clinical Utility of Increased Nuchal Translucency at 11–13 Weeks of Gestation in Twin Pregnancies Based on the Chorionicity
As a standalone screening tool for predicting fetal loss or the need for laser surgery in monochorionic twins, though, NT performs poorly, catching only about 24% of those outcomes at a false-positive rate of roughly 9%. Where it does add value is at the extremes: monochorionic twins with an NT above the 99th percentile had about a 40% rate of fetal loss or need for laser surgery before 20 weeks, compared to an overall rate of about 11% in all monochorionic twins.21PubMed. Increased nuchal translucency at 11-13 weeks’ gestation and outcome in twin pregnancy So in twins, as in singletons, the signal gets stronger as the measurement gets higher.
Measurement Quality and Why It Varies
NT measurement is one of the most operator-dependent tests in obstetric ultrasound. A millimeter of error in either direction can meaningfully change a patient’s risk calculation, so quality control is a genuine concern. In the United States, the Nuchal Translucency Quality Review Program was established in 2004 to standardize training and monitor performance. The program has credentialed more than 6,600 physicians and sonographers and collected over 2.4 million NT measurements. Participants receive quarterly statistical reports comparing their measurements against a standard reference curve, and those whose numbers fall outside expected ranges are flagged for remediation.22Obstetrics & Gynecology. Implementation of a National Nuchal Translucency Education and Quality Monitoring Program
The Fetal Medicine Foundation runs a similar international credentialing system. Performance is monitored against established criteria, and certification requires demonstrating that measurements fall within acceptable parameters.23PubMed Central. Analysis of Quality of Nuchal Translucency Measurements: Its Role in Prenatal Diagnosis If you are offered an NT scan, it is reasonable to ask whether the person performing it holds current certification from one of these programs. A skilled operator measuring carefully and an inexperienced one guessing at the right plane can produce very different numbers from the same baby.
The Emotional Side of a Screening Result
For many expectant parents, the NT scan is their first encounter with the concept that something could be wrong with the pregnancy. A positive or high-risk result introduces a level of uncertainty that can be difficult to sit with, especially during the days or weeks spent waiting for confirmatory testing. Research has found that women who receive positive screening results report significantly higher anxiety afterward compared to those with reassuring results.24PubMed. Maternal anxiety about first trimester nuchal translucency screening and impact of positive screening results
Conversely, when results are reassuring, the scan tends to reduce anxiety and decisional conflict.25TSpace – University of Toronto. Psychosocial aspects of decision making for prenatal screening: nuchal translucency scanning as a new screening alternative The asymmetry is worth being prepared for: a normal result feels great and puts your mind at ease, but an abnormal one can feel catastrophic even though, statistically, most elevated NT results do not end in a serious diagnosis. Understanding that the scan is a screening tool rather than a diagnostic test helps calibrate expectations. A high-risk result means “we should look more closely,” not “something is wrong.”
NT Screening in Different Health Systems
Access to NT screening and how it fits into prenatal care varies considerably depending on where you live. In many European countries and in parts of Asia and South America, combined first-trimester screening with NT is the default pathway offered to all pregnant women. In the United States, NIPT has increasingly become a first-line option, particularly for patients deemed higher risk, and some practices have moved away from routine NT measurement as a result. The debate over whether this shift is wise remains active, precisely because NT picks up structural problems and rare genetic conditions that NIPT was never designed to detect.
Cost plays a role in these decisions at the system level. One analysis of combined first-trimester screening in women of advanced maternal age calculated a cost of about $116 per person tested, with detection rates of roughly 95% for trisomy 21. Offering NIPT to an intermediate-risk group instead boosted detection slightly but at substantially higher cost per detected case.26PubMed Central. A historical and practical review of first trimester aneuploidy screening For health systems working within tight budgets, the cost-effectiveness of NT-based combined screening remains a strong argument for keeping it as the foundation of first-trimester evaluation, with NIPT reserved for patients who screen at intermediate or high risk.